Effects of sodium-glucose co-transporter-2 inhibitors on prognosis after acute myocardial infarction:a Meta-analysis
Objective To investigate the possibility of beneficial effects of sodium-glucose co-transporter-2(SGTL-2)inhibitors on prognosis after acute myocardial infarction(AMI).Methods Randomized controlled trails meeting the inclusion criteria were selected through computer searches of PubMed,Cochrane Library,Em-base,CNKI,Wanfang Database and VIP Journal database from the establishment of the database to August 2024.Outcome indicators included:hospitalization for heart failure;all-cause death;cardiovascular death;MACE events;SGLT-2 inhibitor related adverse effects.Results A total of 6 randomized controlled trails were included in the meta-analysis,with a total of 11 012 patients.The results showed that SGLT-2 inhibitors in addi-tion to standard treatment after AMI reduced the risk of hospitalization for heart failure(RR=0.76,95%CI=0.62～0.93,P=0.01).However,there was no significant difference in the risk of all-cause death(RR=1.00,95%CI=0.83～1.21,P=0.97),cardiovascular death(RR=1.01,95%CI=0.82～1.25,P=0.92),MACE events(RR=1.03,95%CI=0.87～1.21,P=0.76),and SGLT-2 inhibitor related adverse effects(RR=1.03,95%CI=0.96～1.10,P=0.38),compared with placebo.Conclusion The addition of SGLT-2 in-hibitors to standard treatment after AMI is safe and can reduce the risk of hospitalization for heart failure after AMI,but the risks of all-cause death,cardiovascular death and MACE events are not significantly increased or decreased.
NETL
NSTL
万方数据
